Trinity compound research profile
SS-31
A mitochondria-targeted tetrapeptide studied in mitochondrial membrane, bioenergetic, cardiac, skeletal-muscle, and cellular-stress research.
Research overview
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide developed to interact with mitochondrial membranes. Research has examined bioenergetics, oxidative stress, cardiac and skeletal-muscle biology, and disorders involving mitochondrial dysfunction.
Its evidence base includes both preclinical work and clinical development, making it useful for understanding how mitochondrial-targeted compounds translate from mechanism to human studies.
Human evidence summary
The clearest human trial was a small, 12-patient crossover study (where each patient got both the real drug and a placebo at different times, in random order) in people with Barth syndrome. It found SS-31 was NOT better than placebo for walking distance or fatigue scores, though people's leg muscle strength did improve later during an open-label follow-up phase where everyone knew they were getting the real drug (FDA label). A larger, 218-person trial (called MMPOWER-3) in a different condition — mitochondrial myopathy — found no meaningful benefit at all on walking distance or fatigue after 24 weeks, a clear negative result (Karaa et al., Neurology 2023). Despite mixed results, the FDA approved it in 2025 based on the muscle strength improvement seen later in the Barth syndrome study, though this was controversial — reportedly, nearly a dozen FDA reviewers were against approving it (Reuters, Nov 2025).
Preclinical evidence summary
The source data does not detail specific animal studies for SS-31 — the summarized research is centered on the human clinical trials described above and mechanistic/biochemical explanations rather than animal experiments.
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.